Physician profile
Brian Carl Schroer
NPI 1306064852
$48,212.07
in general payments reported to CMS, 2019-2025
22 companies · $40K in 2025
The $40K reported for 2025 was more than what 95% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $140 · 2021: $2,009 · 2022: $2,429 · 2023: $1,764 · 2024: $1,256 · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $5,367 · Travel and Lodging: $3,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,014.00 |
| Food and Beverage | $5,367.49 |
| Travel and Lodging | $3,681.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $43,351.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,515.30 | 2019-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $396.68 | 2019-2024 | Nucala |
| Amgen INC. | $337.88 | 2023-2024 | Tezspire |
| Biocryst US Sales Co., LLC | $247.54 | 2024-2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $243.37 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $222.37 | 2019-2024 | |
| Ars Pharmaceuticals Operations, INC. | $126.06 | 2025 | Neffy |
| Genentech USA, INC. | $125.85 | 2023-2025 | Xolair |
| Regeneron Pharmaceuticals, INC. | $124.89 | 2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $110.12 | 2021 | |
| Aimmune Therapeutics, INC. | $108.29 | 2022 | |
| Sobi, INC | $93.66 | 2023 | |
| Kaleo, INC. | $68.16 | 2019-2022 | |
| Leo Pharma INC. | $26.69 | 2024 | Adbry |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $25.20 | 2019 | |
| Alk-Abello, INC | $17.64 | 2019 | |
| Csl Behring | $16.42 | 2020 | |
| Optinose US, INC. | $14.14 | 2019 | |
| Bio Products Laboratory USA, INC. | $13.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.74 | 2020 | |
| Shire North American Group INC | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Schroer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.